Table 2.
Summary of dynamic transmission economic evaluations in low‐ and middle‐income contexts (all diseases, 2011 to May 2014)
| Field | Frequency | % |
|---|---|---|
| Disease | ||
| Cholera | 1 | 2% |
| Dengue | 2 | 4% |
| HIV | 26 | 46% |
| Human papilloma virus | 2 | 4% |
| Malaria | 11 | 19% |
| Measles | 3 | 5% |
| Pandemic influenza | 1 | 2% |
| Rabies | 1 | 2% |
| Seasonal influenza | 1 | 2% |
| Tuberculosis | 2 | 4% |
| Hepatitis A | 1 | 2% |
| Hepatitis B | 1 | 2% |
| Herpes simplex virus | 1 | 2% |
| HIV and tuberculosis | 2 | 4% |
| HIV and schistosomiasis | 2 | 4% |
| 57 | 100% | |
| Intervention type | ||
| Contact reduction | 1 | 2% |
| Diagnostic | 3 | 5% |
| Mass treatment | 2 | 4% |
| Mass screening and treatment | 2 | 4% |
| Multiple | 18 | 32% |
| Prophylaxis | 5 | 9% |
| Screening | 1 | 2% |
| Treatment | 7 | 12% |
| Vaccine | 14 | 25% |
| Vector control | 4 | 7% |
| 57 | 100% | |
| Primary outcome | ||
| Disability‐adjusted life year | 22 | 38% |
| Elimination | 2 | 3% |
| Infections averted | 40 | 69% |
| Life year | 12 | 21% |
| Mortality | 16 | 28% |
| Net health benefit | 4 | 7% |
| Net monetary benefit | 4 | 7% |
| Quality‐adjusted life year | 14 | 24% |
| 114 | 197% | |
| Model type | ||
| Deterministic compartmental | 33 | 58% |
| Stochastic compartmental | 3 | 5% |
| Individual | 18 | 32% |
| Multi‐model | 3 | 5% |
| 57 | 100% | |
| Sensitivity analysis | ||
| Univariate | 32 | 78% |
| Multivariate or scenario | 27 | 66% |
| Probabilistic | 19 | 46% |
| Structural | 5 | 12% |
| 83 | 202% |